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Key points: We show in HIV+ persons that the CAD effect of an unfavorable genetic background is 
comparable to previous studies in the general population, and comparable in size to traditional risk factors 
and antiretroviral regimens known to increase cardiovascular risk. 
 
Abstract 
Background: HIV-positive persons have increased rates of coronary artery disease (CAD). The relative 
contribution of genetic background, HIV-related factors, antiretroviral medications, and traditional risk 
factors to CAD has not been fully evaluated in the setting of HIV infection. 
Methods. In the general population, 23 common single nucleotide polymorphisms (SNPs) were shown to 
be associated with CAD through genome-wide association analysis. Using the metabochip, we genotyped 
1875 HIV-positive, white individuals enrolled in 24 HIV observational studies, including 571 participants 
with a first CAD event during the 9-year study period and 1304 controls matched on gender and cohort.  
Results: A genetic risk score built from 23 CAD-associated SNPs contributed significantly to CAD 
(P=2.9x10-4). In the final, multivariable model, participants with an unfavorable genetic background (top 
genetic score quartile) had a CAD odds ratio (OR) of 1.47 (95% confidence interval, 1.05-2.04). This 
effect was similar to hypertension (OR=1.36; 95% CI, 1.06-1.73), hypercholesterolemia (OR=1.51; 95% 
CI, 1.16-1.96), diabetes (OR=1.66; 95% CI, 1.10-2.49), >1 year lopinavir exposure (OR=1.36; 95% CI, 
1.06-1.73) and current abacavir treatment (OR=1.56; 95% CI, 1.17-2.07). The effect of the genetic risk 
score was additive to the effect of non-genetic CAD risk factors, and did not change after adjustment for 
family history.  
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Conclusions: In the setting of HIV infection, the effect of an unfavorable genetic background was similar 
to traditional CAD risk factors and certain adverse antiretroviral exposures. Genetic testing may provide 
prognostic information complementary to family history of CAD. 
 
 
 
 
 
 
 
Ac
ce
pt
ed
 M
an
us
cr
ipt
6 
Introduction: 
A major long-term concern in HIV-positive persons includes increased rates and premature onset 
of coronary artery disease (CAD), stroke, and peripheral vascular disease, compared to the general 
population[1-6]. The pathogenesis of CAD in HIV is incompletely understood; a high prevalence of 
smoking, pro-inflammatory and pro-coagulant mechanisms in the context of immunosuppression[7-9], 
adverse viral effects on endothelial and other cells, and deleterious metabolic effects such as dyslipidemia 
and insulin resistance after exposure to certain antiretroviral treatments have been implicated[2, 10-12]. 
CAD has a strong hereditary component[13, 14]. Genome-wide association studies (GWAS) have 
identified common genetic variants that contribute to the risk of CAD in the general population [15, 16]. 
The Myocardial infarction, Assessment of Antiretroviral and Genetic Factors in Human 
Immunodeficiency virus Infection (MAGNIFICENT) Consortium was established with the aim of 
assessing the relative contribution of traditional risk factors, HIV-related factors, antiretroviral regimen, 
and genetic background to CAD in HIV-positive persons. We report here on 571 white HIV+ persons 
who experienced a first CAD event and 1,304 HIV+ matched controls without CAD events in 24 HIV 
observational studies. This represents the most comprehensive genetics-CAD study undertaken in HIV-
positive persons.  
 
Methods:  
Study population, inclusion criteria. The MAGNIFICENT consortium includes 24 HIV 
observational studies from Europe, the US, Australia and Argentina (supplementary material). 
Participants gave written informed consent for genetic testing. The ethics committee of each study center 
approved the study. Applying a case-control design, we defined cases as HIV+, with a first CAD event 
during the study period (4.1.2000-3.31.2009). Controls were HIV+ and event-free during the study 
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period. For each case, we aimed to select 3 controls from the same cohort using risk-set sampling[17]. 
Controls were matched only on gender, to allow analysis of the effect of relevant non-genetic factors. 
Participants with cardiovascular events prior to the study period were excluded. Because most previous 
CAD GWAS in the general population were conducted in populations of European descent[16], the 
present report is restricted to participants of European descent.  
CAD events. CAD events were validated by the treating physician and defined according to the 
Data Collection on Adverse events of Anti-HIV Drugs (D:A:D) study and the MONICA Project of the 
World Health Organisation[2, 18]. CAD events included definite myocardial infarction (MI); possible MI 
or unstable angina; percutaneous coronary intervention including coronary angioplasty and stenting; 
coronary artery bypass surgery; and fatal CAD, which required evidence of CAD before death. All CAD 
events in participating cohorts that occurred during the study period were included.  
Power calculation, genotyping, quality control. We interrogated 23 single nucleotide polymorphisms 
(SNPs) with known CAD association in GWAS meta-analysis in the general population[16]. Using the 
ESPRESSO-CC Power Calculator[19], with projected 600 cases and 1800 controls, the study had an 80% 
power to capture the effect of SNPs with minor allele frequency (MAF) >0.1 and CAD odds ratio >1.25. 
Genotyping was performed on the Metabochip (Illumina, Eindhoven, Netherlands and Broad Institute, 
Harvard University/Massachusetts Institute of Technology), a custom array of 196,725 SNPs from gene 
regions associated with multiple metabolic/cardiovascular traits in GWAS [20]. The Metabochip was 
developed by leader groups in the field to facilitate affordable genotyping of; i) recognized SNPs; ii) the 
genetic regions that carried them, with the goal of discovering causal variants associated with the 
recognized tag SNPs. However, the study was not designed or powered for a Metabochip-wide 
association study, which would require a significance threshold of P<2.5x10-7, i.e. P=0.05 divided by the 
number of SNPs interrogated [196,725]).  
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Participants were filtered based on gender check (heterozygosity testing), and cryptic relatedness. 
We used a modified Eigenstrat approach to identify and exclude population outliers and to control for the 
possibility of spurious associations resulting from residual population stratification[21]. This method 
derives the principal components of the correlations among common (MAF>5%) gene variants, which 
reflect population ancestry, and corrects for those correlations in the subsequent association tests by 
integrating the coordinates of the significant principal component axes as covariates (Eigenstrat 
covariates) in the models.  
Non-genetic CAD risk factors. Covariates were selected a priori based on published CAD effect 
and included in the final model regardless of statistical significance: High total cholesterol (>6.2 
mmol/L[22] or being on lipid-lowering medication), low HDL-cholesterol (<1.04 mmol/L)[22], diabetes 
mellitus (confirmed plasma glucose >7.0 mmol/L [fasting] or >11.1 mmol/L [nonfasting] or taking 
antidiabetic medication)[23, 24], hypertension (systolic ≥140 mmHg or diastolic ≥90 mmHg or taking 
antihypertensive medication), smoking (never, past or current), family history of CAD, age (per 5-year 
increments[25]). HIV-related covariates were defined a priori, based on their contribution to CAD in the 
D:A:D study[25]: CD4+ count and HIV RNA value (closest to the event date), current ART exposure, 
current abacavir exposure, and cumulative exposure to lopinavir and indinavir. Because few patients had 
>2 years exposure and the CAD effect of 1-year and >2 years of treatment was equivalent, these drug 
exposures were considered as binary covariates, i.e. < or >1 year.  
Missing data. Certain covariates were unavailable or had >20% missing data (Supplementary 
Table 3). Mostly, these data were systematically missing in entire cohorts, and therefore assumed to be 
missing at random. This assumption was further checked by comparing summary statistics on non-
missing values across cohorts. There was no evidence that cohorts differed significantly in the distribution 
of important confounders. Therefore, single imputation using predictive mean matching was performed to 
replace missing data for glucose, total and HDL-cholesterol, blood pressure, smoking, family history, 
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duration of lopinavir and indinavir exposure, HIV RNA, and CD4+ count. Missing values were imputed 
using models with the predictors age, sex, abacavir at time of event, region, and case/control status[26]. 
Primary analyses utilized the imputed dataset; sensitivity analyses utilized the non-imputed dataset 
(Supplementary Figures 1B and 3). 
Genetic association analyses. We built two a priori defined genetic risk scores using 23 SNPs 
(or a proxy with r2>0.8) with known CAD association[16] (Supplementary table 2); i) additive genetic 
score (number of CAD risk alleles; heterozygous=1, homozygous=2; i.e. scores ranged from 0 to 46; 
higher scores indicate a higher CAD risk); ii) additive weighted genetic score that takes into account the 
effect size reported in the reference paper[16]. For a SNP with, e.g., a CAD odds ratio of 1.2: reference 
allele=0, heterozygous=0.2, homozygous risk allele=0.4. The numbers obtained for each of the 23 SNPs 
were added to create an individual weighted genetic risk score.  
Statistical analysis. First, we tested the associations of non-genetic factors using a conditional 
logistic regression model[27]. Then, we tested the weighted genetic score plus the 5 Eigenstrat covariates 
and added them to the model, by dividing study participants into 4 genetic score quartiles. We made a 
post-hoc test for an interaction between genetic score and traditional risk factors plus factors that 
contributed to CAD in the D:A:D study[25]. The pseudo-r2 from each conditional logistic regression 
model was used as an estimate of the percentage of explained CAD variability in the study population. 
Analyses were done using PLINK, R, SAS v9.2 (SAS Corporation, Cary, NC) and Stata v12.0 (StataCorp 
LP, College Station, TX). 
Sensitivity analyses. To assess the robustness of results, we repeated the final model in 
participants with; i) complete (non-imputed) data for all covariates; ii) stringent case definition (definite 
MI, coronary artery bypass surgery and fatal CAD, plus corresponding controls); iii) definite MI plus 
corresponding controls; iv) family history excluded from the model.  
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Exploratory genetic association analyses. First, all 196,725 SNPs present on the Metabochip 
were separately tested for association with CAD by conditional logistic regression. Second, to search for 
additional, weaker genetic associations in the regions containing known CAD-associated genes or 
variants, we considered as a group all SNPs located in/near (+/- 5kb) the 23 CAD-associated genes[16] 
and as a separate group the SNPs mapping to genes associated with traits indirectly related to CAD (total, 
LDL-, HDL-cholesterol, diabetes mellitus, fasting glucose, body mass index[20]). The distribution of 
association p-values was compared between these groups and all other SNPs genotyped on the 
Metabochip using the two-sample Kolmogorov-Smirnov test. Third, we evaluated a potential association 
of CAD events with mitochondrial DNA (mtDNA) haplogroups. 
 
Results: 
Study population. We received DNA specimens from 702 cases and 1,849 controls. Twenty-one 
cases and 158 controls were excluded because of registration in the cohort of the control after the event 
date of their matched case (n=124), insufficient DNA quantity or quality (n=42), sample administrative 
error (n=7), non-white self-reported origin (n=4), event occurred after study ended (n=1), missing genetic 
consent (n=1). After genotyping quality control, 97 cases were excluded because they were population 
outliers in the Eigenstrat analysis (n=89) or genetically related with another participant (n=8); 
corresponding controls were also excluded. The final study population included 1,875 participants (571 
cases and 1,304 controls).  
Among the 571 cases, there were 273 definite MI, 48 possible MI or unstable angina, 179 
percutaneous coronary interventions, 32 coronary artery bypass surgeries and 39 fatal CAD. 
Characteristics of participants are shown in Table 1. The median age at first CAD event was 50 years. 
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Cases were older than controls, and more likely to be smokers, have elevated cholesterol and glucose 
levels, a family history, and treatment with abacavir.  
Non-genetic factors contributing to CAD. All covariates were significantly associated with the 
odds ratio of a first CAD event, except low HDL-cholesterol (p=0.29), being on ART at time of CAD 
event (p=0.12), CD4+ count (p=0.44), and HIV viremia (p=0.88) (Figure 2). In the complete case 
analysis (participants without missing covariate data), the sample size was 720 individuals (183 cases, 
537 controls). For the imputed models, the sample size was 1,875 (571 cases, 1304 controls). Conditional 
logistic regression models for the imputed dataset were consistent with the complete case analysis as 
regards direction and effect size of individual covariates (Supplementary Figures 1B and 3). Therefore, 
the final model and the results presented hereafter are based on the imputed dataset.  
 
CAD odds ratio according to genetic risk score. In unadjusted analysis (Table 2), participants in the 3rd 
and 4th genetic risk score quartiles had an increased CAD odds ratio (OR), compared to the 1st quartile 
(OR=1.34; 95% confidence interval [CI], 1-1.79, p=0.05; and OR=1.59 [95% CI, 1.19-2.13], p<0.01, 
respectively). In the final, multivariable model, the additive and the weighted genetic score were 
associated with the CAD odds (P=1.3 x10-4 and P=2.9 x10-4, respectively). Cases were more likely to be 
in the upper 2 genetic score quartiles compared to controls (p=0.01; Supplementary Figure 2). The 
effect of the weighted genetic score (CAD OR=1.47 for the 4th quartile, compared to 1st quartile; 95% 
confidence interval [CI], 1.06-2.04; p=0.02) was similar to the effect of established CAD risk factors and 
certain antiretroviral medications (Figure 2 and Supplementary Table 1A). This included family history 
(OR=2.05; 95% CI, 1.54-2.74), hypertension (OR=1.36; 95% CI, 1.06-1.73), hypercholesterolemia 
(OR=1.51; 95% CI, 1.16-1.96), diabetes (OR=1.66; 95% CI, 1.10-2.49), current smoking (OR=2.48; 95% 
CI, 1.85-3.32), >1 year lopinavir exposure (OR=1.36; 95% CI, 1.06-1.73) and current abacavir treatment 
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(OR=1.56; 95% CI, 1.17-2.07). An unfavorable genetic background had an additive effect on the CAD 
odds, without a significant interaction effect (p=0.60; Figure 3 and Supplementary Table 1B).  
 Relative contribution of clinical, HIV-related and genetic factors. In the final model, 7.5% of 
the CAD odds ratio variability was explained by age, 3.1% by current smoking, 1.9% by family history, 
and 0.9% by genetic score. Smaller percentages were explained by traditional and HIV-related risk 
factors, e.g., 0.7% each by hypercholesterolemia, >1 year lopinavir or current abacavir treatment; 0.5% 
each by diabetes or hypertension (Figure 4). Addition of the genetic score to the clinical model improved 
the fit of the model (2=6.28, p=0.01).  
Sensitivity analyses. Models restricted to participants with non-imputed data, stringent case 
definition (344 cases, 806 corresponding controls), and definite MIs (273 cases, 651 corresponding 
controls) showed similar results, except for a widening of confidence intervals due to reduced sample size 
(Supplementary Figure 3 and 4 and 5). Removing family history did not change the estimates for the 
genetic score (Table 2, Supplementary Figure 6).  
Exploratory metabochip-wide analyses, mtDNA variants. None of the 196,725 SNPs on the 
array were associated with CAD events in a metabochip-wide analysis after correction for multiple testing 
(Supplementary Figure 7). The global distribution of association p-values was not significantly different 
between the 5,070 SNPs within CAD-associated genes, the 36,863 SNPs within genes with a potential 
indirect CAD association[16], and the rest of the SNPs on the Metabochip, indicating an absence of 
enrichment of potentially interesting association signals in the first two groups. mtDNA coverage of the 
Metabochip was found to be unreliable, with an excess of seemingly polymorphic (heteroplasmic) 
mtDNA SNPs; 80% of the participants displayed >1 heteroplasmic SNP out of 135 SNPs mapped to 
mtDNA (total, 5604 heteroplasmic calls; Supplementary results, supplementary figure 8). Results 
were also inconsistent with the complete mtDNA genomes of two participants that had been previously 
Sanger sequenced [28], with 47% unmatched SNPs (64/135 positions, Supplementary Table 4).  
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Discussion: 
This is the first large scale analysis of clinical, HIV-related and genetic risk factors that contribute 
to CAD in HIV-positive persons. Our findings suggest that the effect of an unfavorable genetic 
background on CAD events is comparable to well-established traditional risk factors and certain 
antiretroviral regimens. The genetic risk score, which was defined a priori and captures the joint effect of 
23 common SNPs with known CAD association in the general population[16], remained independently 
associated with CAD after considering multiple non-genetic factors and in sensitivity analyses, suggesting 
that the effect is robust.  
In this HIV+ study population, genetic background explained a larger proportion of the CAD 
variability than did diabetes, hypertension or dyslipidemia, but a smaller proportion than age or current 
smoking. Our exploratory analyses using the metabochip did not provide any novel insight about the 
genetics of CAD in HIV+ persons. This was expected, since the study was designed to assess a panel of 
candidate SNPs with validated CAD association and was not powered for metabochip-wide discovery of 
novel gene variants.  
Family history and genetic risk score contributed to CAD to a similar degree and the effect of the 
genetic score did not change after adjusting for family history. This suggests that family history, which 
may reflect genetic background, but also environmental, social and lifestyle factors shared among family 
members[29, 30], and assessment of common genetic variants capture independent, complementary 
effects on CAD in HIV-positive persons. This is consistent with the results by Ripatti and colleagues, a 
large study in the general population that assessed a similar genetic score [31].  
An unfavorable genetic background had an effect on CAD comparable to certain antiretroviral 
agents known to increase cardiovascular risk. Because the magnitude of the CAD effect of certain drugs 
(e.g. abacavir) is unresolved[32], we based selection of drug exposure covariates on the D:A:D study, the 
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largest ongoing consortium of observational HIV studies[2, 25]. The increased CAD risk associated with 
lopinavir and indinavir is consistent with their previously recorded metabolic effects[2, 33]. Low CD4+ 
count or detectable HIV viremia at the time of the CAD event were not associated with CAD in our 
dataset, consistent with the D:A:D study[34]. Other authors have noted adverse effects of 
immunosuppression on CAD risk[35, 36]. 
Strengths of this study include the assembly of a large study population of HIV-positive persons 
who experienced a first CAD event during a 9-year study period; rigorous quality control of the 
genotyping data; exclusion of population outliers and correction for residual population stratification; 
physician validation of all CAD events; analysis of only SNPs and non-genetic covariates with 
established CAD association; and robust results in sensitivity analyses. Our study was limited by the 
effort required to establish the MAGNIFICENT consortium. Even though HIV+ populations are 
aging[37], the number of HIV-positive persons who have experienced CAD events is limited and not all 
studies include consent for genetic testing. Because demonstration of the CAD effect of 13 of the 23 
SNPs required meta-analysis of >86,000 participants from multiple GWAS in the general population[16], 
additional CAD-associated SNPs with modest effect sizes may emerge from HIV+ study populations 
larger than the MAGNIFICENT consortium. At the time of study design, GWAS-based CAD associations 
were essentially limited to white populations, so we restricted the present analysis to white participants; 
our findings may not be applicable to other populations.  
Our findings suggest that genetic testing may provide prognostic information complementary to 
that afforded by family history, traditional risk factors, and antiretroviral regimen. Particularly in high risk 
patients, knowledge of a deleterious genetic CAD predisposition might further emphasize the rationale for 
aggressive risk factor modification and selection of a CAD-neutral antiretroviral regimen to achieve HIV 
control. The clinical value of genetic testing will rely on demonstration of improved CAD risk 
stratification in prospective studies, as shown by Ripatti in the general population[31, 38]. This was 
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beyond the scope of the case-control design of our consortium. Areas for future investigation include 
addition of genetic score to, e.g. Framingham or D:A:D score in prospective HIV study settings; 
comparison of genetic CAD prediction in HIV-positive vs. HIV-negative populations; and integration of 
genetic background and plasma biomarkers of inflammation, coagulation and endothelial function to 
predict CAD in HIV[7, 39].  
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Table 1: Characteristics of the cases and controls at the matching date.  
 Cases Controls 
Total 571 1304 
Male gender* (%) 91.1 91.3 
Age (years), median (range) 50.0 (22-85.5) 45.0 (16.5-81.3) 
Smoking (%) 
    Never 
    Past 
    Current 
 
22.8 
23.3 
53.9 
 
31.4 
21.6 
46.9 
Hypercholesterolemia (%) 45.5 31.8 
Low HDL-cholesterol (%) 43.1 39.3 
Diabetes mellitus (%) 19.4 13.6 
Arterial hypertension (%) 43.6 31.1 
Family history of coronary artery disease (%) 25.7 15.4 
Receiving antiretroviral therapy (%) 87.7 79.3 
Currently on abacavir (%) 25.6 17.6 
Duration of treatment with indinavir (years),       
    median (range) 
0 (0-8.2) 0 (0-11.3) 
Duration of treatment with lopinavir (years),   
    median (range) 
0 (0-8.0) 0 (0-8.7) 
CD4+ T-cell count (cells/μL), median (range) 497 (11-1688) 500 (10-1905) 
HIV RNA (log copies/mL), median (range) 3.8 (0 -14.6) 3.9 (0-13.6) 
HIV RNA    
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      <50 copies/mL (%) 
      <400 copies/mL (%) 
63.2 
74.1 
60.2 
68.2 
Note. *Cases and controls were matched on gender and cohort.
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Table 2. Odds ratio for CAD according to weighted genetic risk score quartile 
 
 Genetic risk score and 
5 Eigenstrat 
covariates, unadjusted 
for non-genetic 
covariates 
Final model, with family 
history of CAD (Fig. 2) 
Final model, without 
family history of CAD 
(Supp. Fig. 7) 
Genetic risk score 
quartile 2 vs.  
quartile 1 
1.27 (95% confidence 
interval [CI], 0.95-1.69); 
p=0.11  
1.03 (95% CI, 0.74-1.44); 
p=0.84 
1.04 (95% CI, 0.75-1.44); 
p=0.82 
Genetic risk score 
quartile 3 vs.  
quartile 1 
1.34 (95% CI, 1-1.79); 
p=0.05 
1.25 (95% CI, 0.90-1.74); 
p=0.18 
1.25 (95% CI, 0.90-1.72); 
p=0.18 
Genetic risk score 
quartile 4 vs.  
quartile 1 
1.59 (95% CI, 1.19-
2.13); p<0.01 
1.47 (95% CI, 1.06-2.04); 
p=0.02 
1.47 (95% CI, 1.06-2.03); 
p=0.02 
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Figure 1: Summary of the models applied and sensitivity analyses performed. 
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Figure 2: Contribution of traditional CAD risk factors, HIV-related factors and weighted genetic 
score to CAD risk in multivariable analysis  
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Figure 3: CAD risk according to genetic score quartile and number of non-genetic CAD risk factors 
(odds ratio and 95% confidence interval).  
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Figure 4: CAD variability explained by traditional risk factors, HIV-related factors and genetic 
background. 
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Figure Legends 
 
Figure 1. [Figure 1 has no legend] 
 
Figure 2. Results are represented as the estimated effect and 95% confidence interval on the odds ratio of 
a first CAD event for genetic risk score quartile (black dots), HIV-related variables (gray triangles), and 
traditional CAD risk factors (gray squares). Results for the final, fully adjusted model (see  
Supplementary Table 1A) and for the weighted genetic risk score (see Methods section) are shown.  
 
Figure 3. Participants are stratified into 12 groups by weighted genetic score quartile (quartile 1, 2, 3, and 
4) and by the number of non-genetic risk factors (0-2, 3-4 or more than 4 non-genetic CAD risk factors). 
The first group is the reference group (odds ratio=1), i.e. participants with 0-2 non-genetic risk factors 
who are in genetic risk score quartile 1. The sum of all non-genetic CAD risk factors is considered 
(presence of risk factor=1, absence of risk factor=0), including traditional risk factors and additional 
factors that contributed significantly to CAD risk in the D:A:D study [25], i.e. age, past smoking, 
exposure >1 year to lopinavir, exposure >1 year to indinavir, current exposure to abacavir.  
Q, quartile. 
Figure 4. Variability in the CAD odds ratio explained by the final model: 21.1%. Of this, age: 7.5%, 
current smoking: 3.1%, past smoking: 0.4%, high total cholesterol: 0.7%, hypertension: 0.5%, diabetes: 
0.5%, low HDL-cholesterol: 0.1%, family history of CAD: 1.9%, genetic risk score: 0.9%, current ART: 
0.2%, current abacavir: 0.7%, lopinavir (>1 year): 0.7%, indinavir (>1 year): 0.3%, HIV viral load: 0%, 
CD4+ count: 0%.  
LPV, lopinavir. IDV, indinavir. 
 
